Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 36Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Carcinoma, Hepatocellular 15Ovarian Neoplasms 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2zimberelimab 1ulocuplumab 1sotorasib 1sintilimab 1osimertinib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × Bevacizumab × Clear all
NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Recruiting
542 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡